Valganciclovir HydrochlorideThird Party Manufacturing in India

Valganciclovir Hydrochloride works by acting as an L-valyl ester prodrug that rapidly converts into ganciclovir after oral absorption. It inhibits viral DNA synthesis by metabolizing into ganciclovir triphosphate, which competitively inhibits viral DNA polymerase to help the body control cytomegalovirus replication. Unlike standard intravenous ganciclovir treatments, it provides equivalent systemic exposure via an oral route, optimizing outpatient therapy. It is highly effective and well-tolerated in immunocompromised populations.

Therapeutic Uses

• CMV Retinitis: Prescribed for the initial and maintenance treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.
• CMV Prevention: Utilized as a prophylaxis for cytomegalovirus disease in high-risk kidney, heart, and kidney-pancreas transplant recipients.

Why Manufacturers Choose Valganciclovir Hydrochloride

Valganciclovir Hydrochloride third party manufacturing in India is highly sought after by specialized franchise buyers focusing on oncology, immunology, and transplant care segments. Because the manufacturing process for CAS 175865-59-5 requires rigorous containment protocols, partnering with seasoned organizations ensures product integrity. Our partner facilities are WHO-GMP certified, ensuring that each batch meets strict pharmacopeial assay criteria. Celesta Healthcare delivers superior market viability through these WHO-GMP compliant networks, providing high-barrier therapeutic products to discerning global buyers.